CRVS Corvus Pharmaceuticals, Inc.

8-K Current Report

Filed: March 12, 2026

Health Care

Pharmaceutical Preparations

Corvus Pharmaceuticals, Inc. (CRVS) 8-K current report filed with SEC EDGAR on March 12, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 2.02: Results of Operations and Financial Condition

AI Filing Analysis
8-K

Item 2.02 · Results of Operations and Financial Condition

• Q4 and full-year 2025 financial results disclosed via press release (Exhibit 99.1)
• Financials cover period ending December 31, 2025, including balance sheet position

+1 more insights

Other Corvus Pharmaceuticals, Inc. 8-K Filings

8-K Mar 13, 2026

Get deeper insights on Corvus Pharmaceuticals, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.